Testing new treatment combinations for COVID-19
Treatments studied
Part of Infections clinical trials.
This trial studies new drug treatment plans for people who currently have COVID-19. If it works better than standard care, it could improve recovery for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a current COVID-19 infection
- You must be able to take the study drugs without an allergy
- You must not have a known medical reason you cannot take the study drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a higher dose of ivermectin helps people with COVID-19. It looks at how well the treatment works and whether it causes side effects for participants.
This trial tests whether a common blood pressure medication, called an ACE inhibitor, can help treat COVID-19. If you have COVID-19 and are not allergic to this type of drug, you may be able to join.
This trial tests if a medication called nitazoxanide can help people with mild to moderate ulcerative colitis (UC). It may be a treatment option for those not already on strong UC medications.
This trial tests whether the medicine nitazoxanide, taken as a pill, can help people with mild COVID-19 or flu feel better faster and prevent complications. It is designed for people who are generally healthy and can be treated at home.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
Hear when a new COVID trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.